Rating Rationale
December 20, 2019 | Mumbai
Medicamen Biotech Limited
Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.42 Crore
Long Term Rating CRISIL BBB-/Stable (Reaffirmed)
Short Term Rating CRISIL A3 (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its 'CRISIL BBB-/Stable/CRISIL A3' ratings on the bank facilities of Medicamen Biotech Limited (MBL).
 
The ratings continue to reflect MBL's strong track record in the pharmaceutical industry and a comfortable financial risk profile. These strengths are partially offset by the modest scale of operations and large working capital requirement.

Key Rating Drivers & Detailed Description
Strengths
* Strong track record in the pharmaceutical industry
MBL has been operating in the pharmaceuticals industry for about two decades now. Further, the diversified clientele, comprising the government sector and other customers across India, Africa, and Latin America will continue to support the business.
 
* Comfortable financial risk profile
Total outside liabilities to adjusted networth ratio moderated to 0.53 time as on March 31, 2019, from 1.52 times two years ago. Debt protection metrics were also strong, with interest coverage and net cash accrual to adjusted debt ratios of 14.91 times and 1.21 time, respectively, for fiscal 2019.
 
Weaknesses
* Average scale of operations
Intense competition may continue to constrain scalability, pricing power and profitability. Revenue was Rs 122.7 crore in fiscal 2019.
   
* Large working capital requirement
Gross current assets were 244 days as on March 31, 2019, driven by the sizeable debtors (131 days) offered to customers. However, the working capital is partially supported by the substantial creditors of 105 days extended by the suppliers (active pharmaceutical ingredient manufacturers). The working capital cycle is likely to remain stretched over the medium term and hence its efficient management will remain closely monitored.

Liquidity Adequate

Liquidity should remain adequate. Cash accrual, projected at Rs 17 crore and Rs 20 crore in fiscals 2020 and 2021, respectively, should comfortably meet the yearly maturing debt of Rs 0.12 crore and Rs 0.04 crore; the surplus cash will be used as working capital. Thus, bank limit utilisation was moderately low and averaged 22% during the 12 months through October 2019. Current ratio was healthy at 1.87 times as on March 31, 2019.

Outlook: Stable

CRISIL believes MBL will continue to benefit from a strong track record in the pharmaceutical industry.
 
Rating sensitivity factors
Upward factors
* Revenue growth of more than 20%, with the operating margin rising by 200 basis points
* Substantial and sustainable increase in cash accrual
 
Downward factors
* Fall in revenue by more than 10% in comparison to fiscal 2019
* Steep decline in profitability as compared to fiscal 2019
* Larger-than-expected, debt-funded capital expenditure

About the Company

MBL, incorporated in 1993, manufactures pharmaceutical formulations for the overseas and domestic markets. Formulations are based on betalactum, non-betalactum, and cephalosporin drugs. The company is listed on the Bombay Stock Exchange (BSE). In November 2015, Shivalik Rasayan Ltd, another BSE-listed company, along with five persons acting in concert, acquired 44.15% in MBL. MBL has manufacturing facilities in Bhiwadi (Rajasthan) and Haridwar (Uttarakhand).

Key Financial Indicators
Particulars Unit 2019 2018
Revenue Rs crore 122.7 111.6
Profit after tax (PAT) Rs crore 12.03 10.1
PAT margin % 9.8% 9.1%
Adjusted debt/adjusted networth Times 0.14 0.20
Adjusted interest coverage Times 14.91 6.9
Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon
rate (%)
Maturity date Issue size
(Rs cr)
Rating assigned with outlook
NA Bank guarantee NA NA NA 3 CRISIL A3
NA Cash credit NA NA NA 18 CRISIL BBB-/Stable
NA Letter of credit NA NA NA 10 CRISIL A3
NA Proposed fund based bank limits NA NA NA 11.0 CRISIL BBB-/Stable
Annexure - Rating History for last 3 Years
  Current 2019 (History) 2018  2017  2016  Start of 2016
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  29.00  CRISIL BBB-/Stable      29-09-18  CRISIL BBB-/Stable  27-09-17  CRISIL BB+/Stable  01-09-16  CRISIL B/Stable  CRISIL BB-/Stable 
                16-03-17  CRISIL BB-/Stable  09-03-16  CRISIL D   
Non Fund-based Bank Facilities  LT/ST  13.00  CRISIL A3      29-09-18  CRISIL A3  27-09-17  CRISIL A4+  01-09-16  CRISIL A4  CRISIL A4+ 
                16-03-17  CRISIL A4+  09-03-16  CRISIL D   
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 3 CRISIL A3 Bank Guarantee 3 CRISIL A3
Cash Credit 18 CRISIL BBB-/Stable Cash Credit 18 CRISIL BBB-/Stable
Letter of Credit 10 CRISIL A3 Letter of Credit 10 CRISIL A3
Proposed Fund-Based Bank Limits 11 CRISIL BBB-/Stable Proposed Fund-Based Bank Limits 11 CRISIL BBB-/Stable
Total 42 -- Total 42 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Nitin Kansal
Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2154
nitin.kansal@crisil.com


Himank Sharma
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2152
Himank.Sharma@crisil.com


Kishan Gupta
Rating Analyst - CRISIL Ratings
CRISIL Limited
B:+91 124 672 2000
Kishan.Gupta@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL